Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Abeona Therapeutics reports Q2 EPS (14c), consensus (17c) » 16:25
08/10/20
08/10
16:25
08/10/20
16:25
ABEO

Abeona Therapeutics

$2.98 /

+0.12 (+4.20%)

Cash, cash equivalents…

Cash, cash equivalents and short-term investments totaled $107.9 million as of June 30, 2020, compared to $129.3 million as of December 31, 2019. Net cash used in operating activities was $9.5 million for the second quarter 2020. "During the past several months, Abeona has delivered on our goals in clinical development, manufacturing, and regulatory affairs toward bringing urgently needed treatments to patients with RDEB and MPS III," said Joao Siffert, M.D., Chief Executive Officer of Abeona. "Notably, new patients have been treated in our RDEB and MPS IIIA clinical programs, and we expect additional patient enrollment across our clinical programs in the coming weeks. Concurrent with the increased clinical activities, we resumed internal manufacturing operations at our Cleveland campus in June. We have made significant advancements in process development for retrovirus and AAV manufacturing in-house, anticipated to start in late-2020 and early-2021, respectively. In addition, we recently reached general alignment with the CHMP on our proposed path toward a European marketing authorization application for ABO-102 in MPS IIIA, anticipated in 2023. Looking ahead to the potential commercial launches of EB-101 in late-2022 and ABO-102 the following year, we have also strengthened our leadership team, bringing on board a Chief Commercial Officer with significant relevant experience and expertise."

ShowHide Related Items >><<
ABEO Abeona Therapeutics
$2.98 /

+0.12 (+4.20%)

ABEO Abeona Therapeutics
$2.98 /

+0.12 (+4.20%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
ABEO Abeona Therapeutics
$2.98 /

+0.12 (+4.20%)

  • 20
    Dec
Friday
Hot Stocks
Google reports filing supplemental brief in legal case with Oracle » 13:38
08/07/20
08/07
13:38
08/07/20
13:38
GOOG

Alphabet

$1,492.91 /

-8.62 (-0.57%)

, GOOGL

Alphabet Class A

$1,497.28 /

-6.62 (-0.44%)

, ORCL

Oracle

$54.97 /

-0.32 (-0.58%)

Kent Walker, SVP of…

Kent Walker, SVP of Global Affairs, posted to the Google blog, stating in part: "Open software interfaces have been an integral part of the innovation economy. They enable the interoperability that has always let software developers build on each other's work. And the interoperability of open software interfaces is what lets different technologies like apps work together on a variety of devices and platforms: That's why you can take a photo on an Apple phone, save it onto Google's cloud servers, and edit it on a Surface tablet. Our legal case with Oracle turns on our belief that interoperability has been good for innovation, good for developers, and good for consumers... Today, we filed a supplemental brief explaining how the jury in our case heard from over a dozen witnesses, reviewed hundreds of documents, and then unanimously agreed with our position. America's Constitution enshrines the right to a jury trial. The Supreme Court has recognized the important role of a jury in deciding nuanced, fact-specific questions like the ones in this case. A decision in Oracle's favor would limit consumers' freedom to use technologies on a range of devices. It would upend the way developers have always used software interfaces, locking them into existing platforms and giving copyright owners new power to control the building blocks of new technologies. And it would erode the traditional role of the jury in evaluating all the facts relevant to a decision. We look forward to making this case to the Court on October 7." Reference Link

ShowHide Related Items >><<
ORCL Oracle
$54.97 /

-0.32 (-0.58%)

GOOG Alphabet
$1,492.91 /

-8.62 (-0.57%)

GOOG Alphabet
$1,492.91 /

-8.62 (-0.57%)

08/03/20 Goldman Sachs
ADT Inc. price target raised to $17 from $9 at Goldman Sachs
08/03/20 William Blair
Alarm.com downgraded to Market Perform from Outperform at William Blair
08/03/20 Morgan Stanley
ADT Inc. price target raised to $17 from $7 at Morgan Stanley
08/03/20 Credit Suisse
ADT Inc. price target raised to $8.70 from $7 at Credit Suisse
GOOGL Alphabet Class A
$1,497.28 /

-6.62 (-0.44%)

08/03/20 William Blair
Alarm.com downgraded at William Blair on ADT/Google overhang
ORCL Oracle
$54.97 /

-0.32 (-0.58%)

06/24/20 Goldman Sachs
Oracle price target raised to $61 from $58 at Goldman Sachs
06/19/20
Fly Intel: Top five analyst downgrades
06/19/20
Oracle cut to Hold at Argus on limited 'traction' in current environment
06/19/20 Argus
Oracle downgraded to Hold from Buy at Argus
ORCL Oracle
$54.97 /

-0.32 (-0.58%)

GOOG Alphabet
$1,492.91 /

-8.62 (-0.57%)

ORCL Oracle
$54.97 /

-0.32 (-0.58%)

GOOGL Alphabet Class A
$1,497.28 /

-6.62 (-0.44%)

GOOG Alphabet
$1,492.91 /

-8.62 (-0.57%)

ORCL Oracle
$54.97 /

-0.32 (-0.58%)

GOOG Alphabet
$1,492.91 /

-8.62 (-0.57%)

ORCL Oracle
$54.97 /

-0.32 (-0.58%)

GOOGL Alphabet Class A
$1,497.28 /

-6.62 (-0.44%)

Over a week ago
Earnings
Gladstone Land reports Q2 EPS 10c versus 5c in prior quarter » 16:39
08/05/20
08/05
16:39
08/05/20
16:39
LAND

Gladstone Land

$16.27 /

+0.05 (+0.31%)

Reports Q2 revenue…

Reports Q2 revenue $12.6M, consensus $12.69M.Net income for the quarter was approximately $182,000, compared to approximately $3.1 million in the prior quarter. Net loss to common stockholders and non-controlling OP Unitholders during the quarter was approximately $2.1 million, or $0.10 per share, compared to net income to common stockholders and non-controlling OP Unitholders of approximately $976,000, or $0.05 per share, in the prior quarter. Reports Q2 FFO 10.9c

ShowHide Related Items >><<
LAND Gladstone Land
$16.27 /

+0.05 (+0.31%)

LAND Gladstone Land
$16.27 /

+0.05 (+0.31%)

06/10/20 B. Riley FBR
Gladstone Land price target raised to $17.50 from $16 at B. Riley FBR
12/20/19 Wedbush
Gladstone Land initiated with a Neutral at Wedbush
11/26/19 B. Riley FBR
B. Riley FBR starts Gladstone Land with Buy, $13.50 price target
11/26/19 B. Riley FBR
Gladstone Land initiated with a Buy at B. Riley FBR
LAND Gladstone Land
$16.27 /

+0.05 (+0.31%)

Hot Stocks
Oracle to partner with NIH on cloud system to support COVID-19 vaccine trials » 16:32
07/16/20
07/16
16:32
07/16/20
16:32
ORCL

Oracle

$55.81 /

-0.81 (-1.43%)

The National Institute of…

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, recently established the COVID-19 Prevention Network. Its goal is to register millions of volunteers for large-scale clinical testing of vaccines and monoclonal antibodies intended to protect people from COVID-19. As part of this initiative, Oracle developed a Cloud System called the CoVPN Volunteer Screening Registry to identify and screen volunteers who want to participate in COVID-19 clinical trials. Even though the system has been live for less than a week, more than 100,000 people have already registered. This program is expected to support hundreds of clinical trial sites across the United States and internationally by the end of the year.

ShowHide Related Items >><<
ORCL Oracle
$55.81 /

-0.81 (-1.43%)

ORCL Oracle
$55.81 /

-0.81 (-1.43%)

06/24/20 Goldman Sachs
Oracle price target raised to $61 from $58 at Goldman Sachs
06/19/20
Fly Intel: Top five analyst downgrades
06/19/20
Oracle cut to Hold at Argus on limited 'traction' in current environment
06/19/20 Argus
Oracle downgraded to Hold from Buy at Argus
ORCL Oracle
$55.81 /

-0.81 (-1.43%)

ORCL Oracle
$55.81 /

-0.81 (-1.43%)

ORCL Oracle
$55.81 /

-0.81 (-1.43%)

ORCL Oracle
$55.81 /

-0.81 (-1.43%)

Periodicals
Google accused of tracking user activity even after opting out, Reuters reports » 06:00
07/15/20
07/15
06:00
07/15/20
06:00
GOOG

Alphabet

$1,520.25 /

+8.6 (+0.57%)

, GOOGL

Alphabet Class A

$1,522.11 /

+11.3 (+0.75%)

, FB

Facebook

$240.32 /

+1.18 (+0.49%)

, ORCL

Oracle

$57.20 /

+0.66 (+1.17%)

A lawsuit filed Tuesday…

A lawsuit filed Tuesday alleges Google (GOOGL) tracks user activity through hundreds of thousands of apps, even after people opt out of sharing information, Reuters' Paresh Dave reports. Boies Schiller Flexner has represented competitors to Google, including Facebook (FB) and Oracle (ORCL), according to the report. The complaint accuses Google of violating federal wiretap law and California privacy law by logging what users are looking at in news, ride-hailing and other types of apps despite them having turned off "Web & App Activity" tracking in their Google account settings. Reference Link

ShowHide Related Items >><<
ORCL Oracle
$57.20 /

+0.66 (+1.17%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

FB Facebook
$240.32 /

+1.18 (+0.49%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

07/13/20 Mizuho
Alphabet price target raised to $1,650 from $1,560 at Mizuho
07/13/20 Barclays
Alphabet price target raised to $1,600 from $1,400 at Barclays
07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
GOOGL Alphabet Class A
$1,522.11 /

+11.3 (+0.75%)

FB Facebook
$240.32 /

+1.18 (+0.49%)

07/13/20 Benchmark
Roku price target raised to $180 from $153 at Benchmark
07/13/20 Barclays
Facebook price target raised to $275 from $260 at Barclays
ORCL Oracle
$57.20 /

+0.66 (+1.17%)

06/24/20 Goldman Sachs
Oracle price target raised to $61 from $58 at Goldman Sachs
06/19/20
Fly Intel: Top five analyst downgrades
06/19/20
Oracle cut to Hold at Argus on limited 'traction' in current environment
06/19/20 Argus
Oracle downgraded to Hold from Buy at Argus
ORCL Oracle
$57.20 /

+0.66 (+1.17%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

FB Facebook
$240.32 /

+1.18 (+0.49%)

ORCL Oracle
$57.20 /

+0.66 (+1.17%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

FB Facebook
$240.32 /

+1.18 (+0.49%)

ORCL Oracle
$57.20 /

+0.66 (+1.17%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

FB Facebook
$240.32 /

+1.18 (+0.49%)

ORCL Oracle
$57.20 /

+0.66 (+1.17%)

GOOGL Alphabet Class A
$1,522.11 /

+11.3 (+0.75%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

FB Facebook
$240.32 /

+1.18 (+0.49%)

GOOGL Alphabet Class A
$1,522.11 /

+11.3 (+0.75%)

GOOG Alphabet
$1,520.25 /

+8.6 (+0.57%)

Hot Stocks
Rimini Street appoints Gerard Brossard as COO » 09:13
07/13/20
07/13
09:13
07/13/20
09:13
RMNI

Rimini Street

$4.92 /

+0.09 (+1.86%)

, ORCL

Oracle

$57.39 /

-0.13 (-0.23%)

, SAP

SAP

$153.34 /

+0.6 (+0.39%)

Rimini Street (RMNI)…

Rimini Street (RMNI) announced the appointment of Gerard Brossard to the newly created role of executive vice president and COO. Brossard is responsible for Rimini Street's global field operations and the global sales and success of the company's support and application management services for Oracle (ORCL) and SAP (SAP) products. Brossard reports directly to Rimini Street CEO, Seth Ravin. Prior to joining Rimini Street, Brossard served as executive vice president and general manager of Rackspace's global solutions and services group, where he had P&L responsibility for all products, solutions and services.

ShowHide Related Items >><<
SAP SAP
$153.34 /

+0.6 (+0.39%)

RMNI Rimini Street
$4.92 /

+0.09 (+1.86%)

ORCL Oracle
$57.39 /

-0.13 (-0.23%)

RMNI Rimini Street
$4.92 /

+0.09 (+1.86%)

ORCL Oracle
$57.39 /

-0.13 (-0.23%)

06/24/20 Goldman Sachs
Oracle price target raised to $61 from $58 at Goldman Sachs
06/19/20
Fly Intel: Top five analyst downgrades
06/19/20
Oracle cut to Hold at Argus on limited 'traction' in current environment
06/19/20 Argus
Oracle downgraded to Hold from Buy at Argus
SAP SAP
$153.34 /

+0.6 (+0.39%)

07/10/20 Barclays
SAP price target raised to EUR 158 from EUR 120 at Barclays
07/10/20 Deutsche Bank
SAP price target raised to EUR 144 from EUR 120 at Deutsche Bank
07/10/20 Argus
SAP price target raised to $175 from $145 at Argus
07/09/20 RBC Capital
SAP price target raised to $150 from $142 at RBC Capital
SAP SAP
$153.34 /

+0.6 (+0.39%)

ORCL Oracle
$57.39 /

-0.13 (-0.23%)

SAP SAP
$153.34 /

+0.6 (+0.39%)

ORCL Oracle
$57.39 /

-0.13 (-0.23%)

SAP SAP
$153.34 /

+0.6 (+0.39%)

ORCL Oracle
$57.39 /

-0.13 (-0.23%)

ORCL Oracle
$57.39 /

-0.13 (-0.23%)

Over a month ago
Conference/Events
Society for Pediatric Dermatology to hold virtual meeting » 05:55
07/12/20
07/12
05:55
07/12/20
05:55
ABEO

Abeona Therapeutics

$3.01 /

-0.34 (-10.15%)

, AMGN

Amgen

$249.23 /

-2.03 (-0.81%)

, DRMT

Dermavant

$0.00 /

+ (+0.00%)

, NVS

Novartis

$87.02 /

-0.3 (-0.34%)

, PFE

Pfizer

$33.84 /

+0.39 (+1.17%)

, SNY

Sanofi

$50.32 /

-0.24 (-0.47%)

, VRCA

Verrica Pharmaceuticals

$9.51 /

+0.75 (+8.56%)

45th Annual Virtual…

45th Annual Virtual Meeting: SPD2020 will be held on July 10-12. Webcast Link

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

DRMT Dermavant
$0.00 /

+ (+0.00%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
AMGN Amgen
$249.23 /

-2.03 (-0.81%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.84 /

+0.39 (+1.17%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
SNY Sanofi
$50.32 /

-0.24 (-0.47%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

  • 20
    Dec
SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

Conference/Events
Society for Pediatric Dermatology to hold virtual meeting » 04:55
07/11/20
07/11
04:55
07/11/20
04:55
ABEO

Abeona Therapeutics

$3.01 /

-0.34 (-10.15%)

, AMGN

Amgen

$249.23 /

-2.03 (-0.81%)

, DRMT

Dermavant

$0.00 /

+ (+0.00%)

, NVS

Novartis

$87.02 /

-0.3 (-0.34%)

, PFE

Pfizer

$33.84 /

+0.39 (+1.17%)

, SNY

Sanofi

$50.32 /

-0.24 (-0.47%)

, VRCA

Verrica Pharmaceuticals

$9.51 /

+0.75 (+8.56%)

45th Annual Virtual…

45th Annual Virtual Meeting: SPD2020 will be held on July 10-12. Webcast Link

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

DRMT Dermavant
$0.00 /

+ (+0.00%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
AMGN Amgen
$249.23 /

-2.03 (-0.81%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.84 /

+0.39 (+1.17%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
SNY Sanofi
$50.32 /

-0.24 (-0.47%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

  • 20
    Dec
SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

Conference/Events
Society for Pediatric Dermatology to hold virtual meeting » 10:18
07/10/20
07/10
10:18
07/10/20
10:18
ABEO

Abeona Therapeutics

$3.02 /

-0.33 (-9.85%)

, AMGN

Amgen

$247.24 /

-4.025 (-1.60%)

, DRMT

Dermavant

$0.00 /

+ (+0.00%)

, NVS

Novartis

$86.61 /

-0.71 (-0.81%)

, PFE

Pfizer

$33.69 /

+0.24 (+0.72%)

, SNY

Sanofi

$50.25 /

-0.31 (-0.61%)

, VRCA

Verrica Pharmaceuticals

$9.70 /

+0.94 (+10.73%)

45th Annual Virtual…

45th Annual Virtual Meeting: SPD2020 will be held on July 10-12. Webcast Link

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

DRMT Dermavant
$0.00 /

+ (+0.00%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
AMGN Amgen
$247.24 /

-4.025 (-1.60%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.69 /

+0.24 (+0.72%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
SNY Sanofi
$50.25 /

-0.31 (-0.61%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

  • 20
    Dec
SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

Hot Stocks
Abeona Therapeutics announces two presentations related to RDEB program » 07:34
07/10/20
07/10
07:34
07/10/20
07:34
ABEO

Abeona Therapeutics

$3.35 /

-0.07 (-2.05%)

Abeona Therapeutics…

Abeona Therapeutics announced that two poster presentations related to its clinical program for recessive dystrophic epidermolysis bullosa, or RDEB, were featured at the Society for Pediatric Dermatology, or SPD, 45th annual meeting. The first poster includes a detailed analysis of patients with RDEB in the EB-101 Phase 1/2a trial showing that wound healing following EB-101 treatment was associated with improved long-term pain relief. A separate poster provides insights on the significant disease burden associated with RDEB, highlighting data from a literature review on the clinical characteristics, humanistic consequences and economic impact of living with RDEB on patients and their families. The company alsopresented findings from a literature review of 65 studies that provide new insights on the disease burden from the perspective of patients with RDEB and their families. Key observations of the clinical, humanistic and economic burden of RDEB include: Large, chronic wounds comprise a major clinical burden of RDEB and are correlated with pain.Many patients experience anxiety and depression. Parents of children with RDEB reported negative effects on their relationship, choosing to not have more children. 50% of U.S. families characterized the economic impact of managing RDEB as "high" or "severe."

ShowHide Related Items >><<
ABEO Abeona Therapeutics
$3.35 /

-0.07 (-2.05%)

ABEO Abeona Therapeutics
$3.35 /

-0.07 (-2.05%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
ABEO Abeona Therapeutics
$3.35 /

-0.07 (-2.05%)

  • 20
    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.